1. Home
  2. PGZ vs BDSX Comparison

PGZ vs BDSX Comparison

Compare PGZ & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PGZ

Principal Real Estate Income Fund of Beneficial Interest

HOLD

Current Price

$10.14

Market Cap

66.4M

Sector

Finance

ML Signal

HOLD

Logo Biodesix Inc.

BDSX

Biodesix Inc.

HOLD

Current Price

$5.75

Market Cap

62.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PGZ
BDSX
Founded
2012
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Precision Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
66.4M
62.5M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
PGZ
BDSX
Price
$10.14
$5.75
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$32.50
AVG Volume (30 Days)
23.0K
72.0K
Earning Date
01-01-0001
11-03-2025
Dividend Yield
12.26%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$80,173,000.00
Revenue This Year
N/A
$20.75
Revenue Next Year
N/A
$25.05
P/E Ratio
N/A
N/A
Revenue Growth
N/A
22.29
52 Week Low
$8.46
$3.44
52 Week High
$10.59
$31.00

Technical Indicators

Market Signals
Indicator
PGZ
BDSX
Relative Strength Index (RSI) 57.57 31.72
Support Level $9.87 $5.61
Resistance Level $10.09 $6.92
Average True Range (ATR) 0.08 0.54
MACD 0.03 -0.14
Stochastic Oscillator 88.89 9.10

Price Performance

Historical Comparison
PGZ
BDSX

About PGZ Principal Real Estate Income Fund of Beneficial Interest

Principal Real Estate Income Fund is a non-diversified, closed-end management investment company. Its investment objective is to provide high current income with capital appreciation by investing in commercial real estate-related securities. The company does its investments in USA, Australia, Japan, France, Great Britain, Canada, Hong Kong, Germany, Singapore, South Korea, British Virgin Islands and more.

About BDSX Biodesix Inc.

Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.

Share on Social Networks: